PESI live seminar update: Due to concerns with coronavirus (COVID-19) all live, in-person seminars through April 24th are being changed to digital format. Click here for more information about the status of live in-person seminars. Click here for Online Learning Options.
Peter Buch, MD, AGAF, FACP, is a clinical gastroenterologist with over 30 years of specialty experience to draw from.He completed his internship and Residency in Internal Medicine and his Fellowship in Gastroenterology at Long Island Jewish-Hillside Medical Center.His current practice is in Manchester, Connecticut, where he has assembled a team that treats all GI conditions.“We pride ourselves on giving each patient the time and care they need,” says Dr. Buch. This has resulted in outstanding patient evaluations and much better outcomes.
Dr. Buch has a passion for teaching.His expertise has been shared with experienced clinicians and advanced level students.He teaches at the University of Connecticut School of Medicine, the University of New England College of Osteopathic Medicine, the Frank H Netter School of Medicine/Quinnipiac University and the University of Connecticut APRN School.Dr. Buch’s style is case-based, practical, very interactive and fun.Upon completion of his seminar, you will have a virtual toolbox of new clinical ideas.He ALWAYS learns from his audiences and looks forward to learning with you!
Financial: Peter Buch is an Associate Clinical Professor of Medicine at the University of Connecticut School of Medicine; and at the University of New England College of Osteopathic Medicine. He is an Association Professor at Frank H. Netter School of Medicine/Quinnipiac University. Dr. Buch receives a speaking honorarium from AbbVie Synergy Pharmaceuticals. Peter Buch receives a speaking honorarium from PESI, Inc.
Non-financial: Peter Buch is a member of the American College of Gastroenterology where he serves on the FDA Committee and the Patient Care Committee.
Dr. Buch references the use of antidepressants for Irritable Bowel Syndrome; and the controversial use of Fibrotest to evaluate patients with fatty liver disease who may have fibrosis of the liver. Dr. Buch indicates he wishes to present a fair and balanced approach to practitioners regarding such practices.